NEWS

WIRES

OTHER

Mach One Corporation Begins Hyper Immunization of Cows

Mach One Corporation (PINKSHEETS: MNCN) is pleased to announce the hyper immunization of cattle at a large dairy in Wisconsin in preparation of a program of colostrums replacement under Mach's proprietary replacement program.

The hyper immunization of the target group with a variety of vaccinations will allow for the future manufacture of the Company's Immunogam(TM) product using the antibody rich serum taken from these cows and fed back specifically through Immunogam(TM) to the calves born to the dairy.

The test of the proprietary Immunogam(TM) product will allow for the Company to prove its effectiveness to the dairy industry and allow for mass distribution of the product.

The program will be administered under the strict supervision of a veterinarian who will also test the calves for absorption levels of IgG and will officially sign off on all results that will be made public on the Company's website.

Monte B. Tobin, CEO of Mach One, said, "We are thrilled to start the process in order to prove the effectiveness of Immunogam(TM) to the dairy industry. We fully expect each newborn calf to absorb 100% of the necessary IgGs and to eliminate Failure of Passive Transfer that currently plagues the dairy industry. Add to that our patented process and proprietary methods to add antibodies to the product and we believe we will be able to eliminate much of the disease that affects dairy cattle as well."

Also, Mr. Tobin will be featured in an exclusive Market News First interview May 7, 2007 at 12:45 PM CDT with MN1 "Inside the Trades" host Saul Albom on www.mn1.com in a follow-up conversation to the interview Mr. Tobin gave last week.

About Mach One Corporation:

The company (www.machonecorp.com) specializes in Immune or Gamma Globulin replacement (IgG) for the equine and bovine markets. Through its subsidiary company VDx, Inc., the company plans full scale manufacturing and distribution Immunogam(TM), a colostrums replacement, supplement and prophylactic, in sterile powder form, that can be administered orally or intravenously. VDx is also further developing a proprietary procedure to allow for large scale manufacturing of colostral replacement products for market along with an added ingredient for mastitis and Johnnes disease.

About MN1.com:

Market News First is an online, market news provider that brings investors current news on the market. Market News First is the only online, live IPTV website that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE.

Through daily, live interviews, we bring you up to date on all the established companies and inform the investors of the newest opportunities within the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies to deliver answers to the questions that investors may ask and provides them insight into the companies' present condition and future plans.

"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.